Physician profile
David Charles Olansky
NPI 1689641227
$12,841.61
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,853 · 2020: $220 · 2021: $961 · 2022: $8,510 · 2023: $1,005 · 2024: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Barco, INC. | $8,000.00 | 2022 | |
| Merz North America, INC. | $2,381.47 | 2019-2023 | |
| Abbvie INC. | $425.00 | 2019-2024 | |
| Leo Pharma INC. | $283.98 | 2019-2023 | Adbry |
| Lilly USA, LLC | $187.53 | 2019-2024 | Olumiant, Taltz |
| Janssen Biotech, INC. | $158.81 | 2021-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $138.43 | 2019-2023 | Winlevi |
| Dermavant Sciences, INC. | $127.64 | 2022-2024 | Vtama |
| Amgen INC. | $126.29 | 2022-2024 | Otezla, Enbrel |
| Pfizer INC. | $121.70 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $107.66 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $105.05 | 2023 | Dupixent, Libtayo |
| Genentech USA, INC. | $85.82 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.61 | 2020-2024 | Jublia |
| Incyte Corporation | $67.68 | 2023-2024 | Opzelura |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.47 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $55.24 | 2020-2021 | |
| Genzyme Corporation | $38.09 | 2019-2021 | |
| Ucb, INC. | $35.55 | 2019-2021 | |
| Almirall LLC | $30.45 | 2022-2024 | Seysara |
| Prugen, INC. Pharmaceuticals | $25.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.53 | 2024 | |
| Epi Health, LLC | $22.58 | 2022 | |
| Organogenesis INC. | $22.39 | 2023 | Puraply |
| Biofrontera INC. | $20.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.72 | 2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $19.12 | 2022 | |
| Celgene Corporation | $17.72 | 2019 | |
| Stemline Therapeutics INC. | $13.58 | 2020 | |
| Merck Sharp & Dohme LLC | $12.84 | 2019 | |
| Dermira, INC. | $12.81 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Olansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.